GEN Reports on Recent Progress in Alzheimer’s Research

The global market value of Alzheimer's disease therapeutics could soar to the $8 billion range once therapeutics are approved that actually change the course of the disease, reports Genetic Engineering & Biotechnology News (GEN).
 
 
GEN
GEN
 
Spread the Word
Listed Under

Tags:
Gen
Biotechnology
Alzheimer S

Industrys:
Biotech
Science

Location:
New Rochelle - New York - US

Subject:
Reports

Aug. 7, 2012 - PRLog -- Contact: John Sterling, Editor in Chief, Genetic Engineering & Biotechnology News
(914) 740-2196, jsterling@genengnews.com

GEN Reports on Recent Progress in Alzheimer’s Research   

New Rochelle, NY—The global market value of Alzheimer's disease therapeutics could soar to the $8 billion range once therapeutics are approved that actually change the course of the disease, reports Genetic Engineering & Biotechnology News (GEN) (http://www.genengnews.com). The current therapeutic market is valued at $3 to $4 billion, shared among drugs that temporarily delay disease progression or address the symptoms but do not alter the underlying disease, according to a recent issue of GEN. (http://www.genengnews.com/gen-articles/new-hope-for-alzheimer-s-disease/4186)

“Despite all the research on amyloid plaques and neurofibrillary tangles there is still a debate on whether these biological phenomena are causative or symptomatic of Alzheimer’s,” said John Sterling, Editor-in-Chief of GEN. “Once scientists can clearly and unequivocally define key factors related to the actual biology of the disease itself, therapeutic advances could take place much more quickly.”

More than 150 companies are working in the Alzheimer's space, including approximately 15 multinationals and 30 generics companies. A number of these firms are taking innovative approaches to tackling this extremely debilitating disease. For example, the USPTO in March granted a patent for Antisenilin, developed by Intellect Neurosciences. This therapy, which targets either end of ß-amyloid, is in Phase III trials.

Baxter has a Phase III program under way for Gammagard, a naturally occurring plasma-derived immunoglobulin for moderate-stage AD patients. The trial runs until February 2013. Phase II results suggest Gammagard may positively affect brain atrophy and cognition. The compound already is approved for immunodeficiency diseases.

Other companies covered in the GEN article include AstraZeneca, Roche, TransTech Pharma, Astex Pharmaceuticals, Memory Pharmaceuticals, Sanofi-Aventis, Eli Lilly, GE Healthcare Life Sciences, and Charles River Laboratories.

For a copy of the August issue of GEN, please call (914) 740-2146, or email: pbartell@genengnews.com

Genetic Engineering & Biotechnology News (http://www.genengnews.com), which is published 21 times a year by Mary Ann Liebert, Inc. (http://www.liebertpub.com), is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Translational Medicine.
End
Source:
Email:***@liebertpub.com Email Verified
Phone:914-740-2100
Zip:10801
Tags:Gen, Biotechnology, Alzheimer S
Industry:Biotech, Science
Location:New Rochelle - New York - United States
Subject:Reports
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Mary Ann Liebert, Inc., publishers PRs
Trending News
Top Daily News
Top Weekly News



Like PRLog?
9K2K1K
Click to Share